Revealing the link between macrophage in microenvironment of osteosarcoma and poor prognosis by utilizing the Integrated analysis

Sikuan Zheng¹, Jie Peng², Jingyu Jia¹, Tianlong Wu¹, Xigao Cheng¹

¹Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, China; ²Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, China

Introduction

As the most common type of primary malignant bone tumor, osteosarcoma (OS) has a poor prognosis after treatment with a combination of surgery and chemotherapy⁵. Local pain, together with local swelling and limitation in joint motion, constitutes the typical signs and symptoms of osteosarcoma and causes great pain to the patients in their daily lives. If untreated, osteosarcoma would progress relentlessly with both local and systemic pain, and result in death within a few months. Even though modern multimodality treatment could significantly improve both tumor resectability and long-term prognosis of the patients, there are still 25-35% of the patients with initially non-metastatic disease tending to develop metastasis subsequently. Therefore, to avoid chemo-resistance, reduce lung metastasis, improving clinical outcomes, and understanding the mechanisms underlying disease progression, the interaction between the different cellular players of the tumor microenvironment (TME), along with the extracellular matrix (ECM), recapitulation them is one strategy².

At present, DNA microarray technology has attracted great interest among researchers. Known as “gene chip” technology also, it integrates molecular genetics with computer science on a great scale. The technology can demonstrate the simultaneous expression in details of the entire genome quickly. Since high-throughput technology has been used in many fields, detecting abnormal genomic changes in OS patients via OS chips by detecting the expression levels throughout the genome is a useful way.
Recently, many researchers have used this technology to increase knowledge on changes in OS in terms of cells and molecules in a more comprehensive way. In 2014, Yang et al.\(^2\) carried out a meta-analysis of the OS microarray data to understand the underlying OS mechanism in a better way. As for this study, the data acquired from different microarray platforms and the results of OS tissue samples and cell lines were selected as the data source. It is demonstrated in this study that either the “extracellular matrix (ECM)-receptor interaction” or the “cell cycle” was a highly enriched KEGG pathway, and PTBP2, RGS4, and FXYD6, and several other hub genes were also identified in this study.\(^2\) Either the overexpression of c-fos (FOS) or the runt-related transcription factor 2 (RUNX2) might exert a specific effect in OS; and in the patients with OS, expression of RUNX2, in particular, might act as a marker of their chemotherapy failure.\(^4,5\)

Although these studies show a list of DEGs, there are often inconsistencies among the studies because of the small sample size and the limitations of different results acquired (by other laboratory procedures, microarray platforms, and analytical technologies) from different groups. Recent studies have shown that integrating the expression data of genes from multiple sources systematically, known as a meta-analysis, could improve the statistical ability to detect DEGs and assess heterogeneity and possibly lead to more robust predictions reproducible and more accurate.

Therefore, we integrated large volumes of DNA microarray data sets for meta-analysis. We collected 6 data sets in the GEO database and performed a meta-analysis using the expression matrix. 218 differential genes were obtained through the integration analysis of t-test and z-score. Through the analysis of KEGG and GO pathways, it was found that macrophage-related pathways were activated. However, the macrophages marker (CD163) is highly expressed in osteosarcoma and is associated with prognosis. Also, through analyzing EPIC of the four RNA-seq data sets screened from the database, we found that macrophages increased in tumors compared with para-carcinoma cells. Combined with the above analysis, we found increased macrophages in osteosarcoma and confirmed that the tumor’s immune microenvironment correlated.

**Material and methods**

**Selection of microarray datasets**

Referring to the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), which was published in 2009, we searched the in the National Center for Biotechnology Information (NCBI, website: http://www.ncbi.nlm.nih.gov/geo/) for databases of Gene Expression Omnibus (GEO) in a comprehensive way. We used the keyword “osteosarcoma” in our search. It’s required that the datasets should meet the criteria as follows: 1) the study organisms must be Homo sapiens; 2) the datasets must contain both samples of osteosarcoma patients and samples of corresponding normal tissues. The studies would be excluded in the following circumstances: 1) they were studies on cell lines; 2) they were free of traceability in literature; 3) they were studies on DNA methylation; 4) they were studies based on miRNA; and 5) they lacked both cases and controls. In fact, two independent analysts have searched the original studies and selected the data required, and any disagreement between them was finally solved by a third analyst to which they referred for consultation.

**Meta-analysis of multiple microarray datasets**

It was from GEO’s database that files (.CEL) on microarray datasets meeting the criteria for inclusion were downloaded. Using R statistical software (website: http://www.r-project.org/) to integrate the genes from datasets, common genes were obtained. Then, using R statistical software, a meta-analysis of expression profiles of common genes was performed by a combination of p-values and Z scores. The combination of p-values (pval_test) has both test-statistic and p-value included. Common genes were performed a meta-analysis by packages of MAMA, mataMA, affyPLM, CLL, and RankProd. In using R statistical software to perform two meta-analyses, we used the combination meta-analysis of p-values (with the threshold being absolute value greater than 5) and Z-scores (with the threshold being absolute value greater than 4) to serve as the cut-off criteria and identified a list of (upregulated or downregulated) DEGs.

**Analysis of GO annotations and KEGG pathway enrichment**

It is of vital importance to identify the biological characteristics of DEGs. Based on the meta-analysis results, enrichment analysis was used to evaluate the most significant DEGs. Then, WEB-based Gene Set Analysis Toolkit (website: http://www.webgestalt.org/option.php) was applied to perform analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and annotation of gene ontology (GO), to identify the DEGs that were of the most significance.

**GSEA pathway analysis and EPIC**

To investigate the function of immune cells in osteosarcoma, we provided a text-based GMT (Gene Matrix Transposed) file, in which one of lm22 was defined for each line with their markers.\(^5\) Then pathway analysis of Gene Set Enrichment Analysis (GSEA) related to genes ranked by t-values in the meta-analysis was performed. Lm22 were as follows: the B_cells naive, the B_cells memory, the Plasma_cells, the T_cells CD8, the T_cells CD4 naive, the T_cells CD4 memory resting, the T_cells CD4 memory activated, the T_cells follicular helper, the T_cells regulatory (Tregs), the T_cells gamma delta, the NK_cells resting, the NK_cells activated, the Monocytes, the Macrophages MO, the Macrophages M1, the Macrophages M2, the Dendritic_cells resting, the Dendritic_cells activated, the Mast_cells resting, the Mast_cells activated, the Eosinophils and the Neutrophils. To investigate the proportion of immune cell
components in osteosarcoma, we put four RNA-Seq datasets from GEO to a tool named EIPC\(^7\). The tool is known as “Estimate the Proportion of Immune and Cancer cells”, or EPIC for short. This tool compares the level of gene expression in a tumor and a library of the gene expression profiles from specific cell types as can be found in tumors and uses the comparison result to predict the amount of each type of cells that exist. EPIC’s predictions have been confirmed to be accurate by experimental measurements of several human tumors.

**Construction of PPI network**

The database of Search Tool for the Retrieval of Interacting Genes (known as STRING) (website: http://string-db.org) provides data on protein-protein interactions (known as PPIs)\(^8\). With the confidence score \(\geq 0.7\) as the criterion for significance cut-off, we used STRING to chart a PPI network of DEGs, aiming to have a profound understanding and prediction of the identified DEGs’ cellular functions and biological behaviors. Also, Cytoscape software was used for visualization of the PPI network\(^9\).

**Selection of hub genes and modules**

PPI network was conducted calculation in terms of its degree, closeness, and betweenness using Cytoscape software. The degree of a node refers to the average number of edges (or interactions) occurring on it\(^10\). In accordance with the degree of a node, identification of the hub genes was made. For selecting the clustering modules of PPI network with the most significance in Cytoscape, Molecular Complex Detection (MCODE) software was used, of which the degree cut-off=2, the cut-off of node score=0.2, the k-core=2, while the max. Depth=100.

**Survival analysis of hub genes**

Based on 50 osteosarcoma patients in one dataset (GEO21257), in terms of patient survival, the relevance of the genes identified was displayed in the form of Kaplan-Meier plot.

**Results**

**Identification of DEGs by meta-analysis**

In accordance with the inclusion criteria, six GEO datasets as follows were obtained from the NCBI: GSE11414, GSE12865, GSE14359, GSE16102, GSE42352, GSE42572 (see the “Materials and Methods”, Figure 1A). 173 samples of osteosarcoma and 29 samples of normal tissues in total were used in meta-analysis. Using Affymetrix gene chips and Illumina gene chips, the GEO Platform (GPL) files were obtained from total six datasets (Table 1). Total 10390 common genes were identified throughout all datasets, and in accordance with the combination of p-values and Z scores, a meta-analysis of the expression profiles of multiple genes was performed on two platforms. Total 218 DEGs were identified in accordance with the combination of t-values (with the threshold being 5) and Z scores (with the limit being 4) (Figure 1B). And total 75 genes down-regulated and 142 genes upregulated were identified (see supplementary materials Table S1).

**Analysis of GO term and KEGG pathway enrichment**

To make a deep investigation of the DEGs’ functions, DEGs were put into the category of functional GO and KEGG, and then an analysis of pathway enrichment was carried out. Consistent with the p-value (P<0.05), selecting the top ten terms among all terms enriched in the KEGG category was made. The most enriched terms regarding the DEGs in KEGG pathway were Apoptosis (hsa04210), Lysosome (hsa04142), Calcium signaling pathway (hsa04121), Cell adhesion molecules (hsa04514), Endocytosis (hsa04144) (Figure 2A). For cellular components, it’s demonstrated by the results of GO analysis that there was separate enrichment of DEGs in cytoplasmic vesicle part (GO:0044433), lysosome (GO:0005764), lytic vacuole (GO:0000323), and secretory granule (GO:0030141) (Figure 2B). Based on the above pathway analysis, we believed that osteosarcoma’s occurrence and development were closely related to macrophages. For Cellular Component analysis in GO term, the significant gene sets in the enrichment results were shown in a directed acyclic graph (DAG), and the diagram showed that the
Lysosomal related pathways were closely associated with the development of OS (Figure 2B). We conducted GSEA analysis based on a negative z score and get a similar conclusion (see supplementary materials Table S2-4).

**LM22 GSEA pathway analysis and EPIC analysis in the tumor microenvironment of osteosarcoma**

To investigate the immune-related characteristics that might be involved in immunoreactive osteosarcoma, a GSEA enrichment prediction of the tumor microenvironment was conducted. Newman et al. constructed a leukocyte signature matrix that enabled further applications on immune infiltration by applying CIBERSORT (short for cell-type identification by estimating relative subsets of RNA transcripts), which was a new approach that allowed the RNA mixtures to be analyzed on a large scale. Based on LM22 gene sets, GSEA analysis results showed that the monocyte pathway was significantly activated (Figure 3A). Compared with the normal group, genes associated with monocytes were significantly upregulated in osteosarcoma patients than normal tissues.
osteosarcoma tissues (Figure 3B). We also performed EPIC analysis to estimate the number of immune cells existing in the tumor microenvironment of osteosarcoma. EPIC was made based on a unique collection of RNA-seq reference gene expression profiles coming from the circulating immune cells or the tumor invasive non-malignant cells. We obtained four datasets in the GEO dataset, including GSE126209, GSE87624, GSE99671, and GSE57925 (Table 2). Consistent with GSE analysis, we concluded that the proportion of macrophages in osteosarcoma samples was greater than that in normal samples. The proportion of macrophages was significantly increased while the proportion of lymphocytes had no statistical changes in immunoreactive osteosarcoma compared with normal tissues.

**Screening of hub gene and module from PPI network and the survival analysis**

In the first place, DEGs’ PPI network was determined. Based on the STRING database, this PPI network was composed of 217 nodes as well as 274 edges. As for the top six hubs with degree centrality as screened from the PPI network, they were taken as the hub genes (Figure 4A). For these hub genes, they included CD209 molecule (CD209), CD34 molecule (CD34), CD86 molecule (CD86), CD163 molecule (CD163), CD80 molecule (CD80) and Fc fragment of IgG receptor IIb (FCGR2B). Most important of all, these hub genes were all upregulated in osteosarcoma tissues (Figure 4B). To make an investigation of the relationship between these genes and the patient prognosis, the hub genes were carried out a survival analysis. We found that GSE21257

![Figure 4. Establishment of PPI network. (A). Macrophage-related modules obtained from PPI network of DEGs using the MCODE software. (B). The expression of Macrophage-related modules between osteosarcoma versus normal tissue in GEO dataset (GSE42352).](image)

![Figure 5. The expression of the marker (CD163) in macrophages and its prognosis. (A). meta-analysis for comparing CD163 expression in the osteosarcoma and para-carcinoma tissues based on six GEO datasets. The forest plot shows that CD163 expression is upregulated in cancer. (B). CD163 significantly correlates with poor prognosis of OS(GEO21257).](image)
contains only cases without normal. It is not used for meta-
analysis, but only for survival analysis. Our study found that
the expression of CD163, as the marker of macrophages,
was associated with the OS of the osteosarcoma patients in
a negative way (OS_HR=2.2889, P=0.0497). These results
suggested that macrophage was a risk factor in patients with
osteosarcoma (Figure 5A-B).

Discussion

We collected all the osteosarcoma data sets in GEO
datasets and selected the data sets meeting the requirements
for meta-analysis. According to the two cut-off values of
t-values and Z scores, 218 DEGS were determined. Next,
its shown by analysis of GO term as well as KEGG pathway
enrichment that macrophages played a significant role in the
development of osteosarcoma. EPIC analysis indicated that
macrophages were increased in osteosarcoma, and Im22
GSEA pathway analysis suggested abnormal activation of
the macrophage pathway. In addition, PPI network analysis
showed that the macrophage module was the core module,
and survival analysis indicated that high expression of the
marker of macrophage (CD163) predicted a worse prognosis
in patients with osteosarcoma.

The tumor microenvironment (known as TME) is constituted
by various cell types (e.g., the endothelial cells, the fibroblasts,
and the immune cells) as well as extracellular components
(e.g., the cytokines, the growth factors, the hormones, and
the extracellular matrix) as surrounding the tumor cells and
receiving nourishment from a vascular network. In terms of
TME, it does not only exert an important effect on initiation,
progression, and metastasis of tumors but also plays a crucial
role in the therapeutic efficacy of tumors4. It should be noticed
that the therapeutic efficacy could be supported or obstructed
by the immune cells. Still, the activation status and location
of the immune cells themselves in the TME could be varied.
Based on EPIC, this study used the gene expression matrix
of patients with osteosarcoma to find that the proportion
of macrophages in the microenvironment of osteosarcoma
increased compared with the normal tissues, and the survival
analysis found that the change had a significant impact on the
survival of the patients, which deepened the understanding
of the microenvironment of osteosarcoma and enhanced the
knowledge of osteosarcoma.

There has been strong evidence showing that tumor-
associated macrophages (known as TAMs) form a key
regulator for a therapeutic response within the TME. For
bone marrow monocytes, which come from progenitor cells
of bone marrow, they can enter the tumors through blood
circulation and then be differentiated into macrophages
later. Based on their polarization status, macrophages can be
classified into subcategory M1 and subcategory M2.
Subcategory M1 macrophages could be activated by Th1
cytokine interferon γ (known as IFNγ) and the microbial
products. In contrast, subcategory M2 macrophages would
differentiate as a consequence of Th2 cytokines, with IL-4,
IL-10, IL-13, and so on included11,12. In the context of TAMs,
it’s considered that M1 macrophages could exert an effect
of tumor-destroying, while the M2 macrophages could
promote the development of tumors. Being both plastic
and reversible, M1 and M2 TAMs could have their functional
polarization regulated by TME significantly13,14. Studies have
shown that cd163 was the marker of M2 macrophage in
bone marrow15. Therefore, this study first indicated that the
M2 macrophage in TME of osteosarcoma increased and was
harmful to osteosarcoma patients.

During the therapeutic process of cancer, a misdirected
response to tissue repair with coordination by TAMs could
be induced by the chemotherapeutic agents16. This might
promote the growth of tumors and limit the anti-tumor
activity. It has been demonstrated by evidence both in vitro
and in vivo that the resistance to some chemotherapeutic
agents (for example, the 5-fluorouracil, the doxorubicin, the
gemcitabine, the paclitaxel, and the platinum compounds) and
anti-VEGF treatment could be mediated by TAMs17,21. Myeloid-
derived suppressor cells could migrate to the tumor site
actively as well and then differentiate into TAMs rapidly22. With
the enhancement of the knowledge on tumor immunity and
immune escape mechanisms, some tumor immunotherapies
that are new and more effective have come into existence. As
for methods that destroy the immune tolerance to TME (short
for tumor microenvironment), make effective prevention of
tumor immune escape and stimulate antitumor immunity in
the body more effectively, while not making stimulation or
even suppression of the negative immune responses, they
are novel design approaches for new modalities of therapy.
Combined with previous studies, this study suggested that
M2 macrophages cells in osteosarcoma may act as a potential
new therapeutic target.

As for macrophages’ functions, they were as changeable
as their lineages and had a significant effect on regulating
normal homeostasis and the development of diseases23,24. Increasing evidence showed that macrophages played a
principal role in the remodeling of normal and diseased
tissues, such as angiogenesis, breakdown of basement
membranes, filtration of leukocytes, suppression of immunity,
and so on23. Therefore, with TME (tumor microenvironment),
macrophage has become a drug target with a central role for
various states of diseases.

As a receptor tyrosine kinase that is expressed on
macrophages residing in tissues, at the sites of inflammation,
RON (Recepteur d’Origine Nantais) would bind to the
macrophage-stimulating protein (known as MSP) upon
activation of proteolysis25. As for both prostate and breast
cancer models, it has been shown that RON signaling in
macrophages could have CDB+ T cells’ anti-tumor functions
impaired, thus promoting the growth of tumors and outgrowth
of metastasis, respectively26,27. The pharmacologic blockade
against RON kinase by the inhibitor such as BMS-777607/
ASLANO02 could boost the number of TNF-α-secreting
macrophages pro-inflammatory and reduce outgrowth
of metastasis in lungs in the breast tumor model of PyMT-
MSP27. Therefore, drugs targeting macrophages may be a
new therapeutic target for osteosarcoma.

To the best of our knowledge, this view about M2 macrophages in osteosarcoma has never been reported in the literature before, so our findings not only suggested that changes in the immune microenvironment in osteosarcoma but also may become a new direction of immunotherapy. This integrated analysis may help to identify potential targets for osteosarcoma treatment, explore relevant pathways, increase the rigor of preclinical, experimental design, and provide a new treatment method for osteosarcoma.

In conclusion, this study has systematically validated the results of the studies carried out previously and filled up the gap in OS’s field on a large-scale meta-analysis. Also, for the hub gene (CD163) and the macrophage cell capable of being used as a novel biomarker in promoting early diagnosis and development of therapeutic approaches, the evaluation was made, which provided strong evidence for making individualized treatment of OS based on genomes in the future.

Author contribution

SZ, JP and XC conceived and designed the study, and drafted the manuscript. SZ, JJ, TW and XC collected, analyzed and interpreted the data. SZ and JP revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

References

1. Li Z, Dou P, Liu T, He S. Application of long noncoding RNAs in osteosarcoma: Biomarkers and therapeutic targets. Cell Physiol Biochem 2017;42(4):1407-19.
2. Rebelo SP, Pinto C, Martins TR, et al. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials 2018;163:185-97.
3. Yang Z, Chen Y, Fu Y, Yang Y, Zhang Y, Chen Y, Li D. Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data. BMC Med Genet 2014;15:80.
4. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 2010;10:202.
5. Wang Q, Liu H, Wang Q, Zhou F, Liu Y, Zhang Y, Ding H, Yuan M, Li F, Chen Y. Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9. PLoS One 2017;12(6):e0180558.
6. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett 2017;378:61-8.
7. Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 2017;6:e26476.
8. Szkarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-52.
9. Szkarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-52.
10. Lin C, Wang K, Chu Z, Wang K, Deng J, Obaidat MS, Wu G. Hybrid charging scheduling schemes for three-dimensional underwater wireless rechargeable sensor networks. J Syst Softw 2018;146:42-58.
11. Qian B, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell 2010; 141(1):39-51.
12. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 2015;36(4):229-39.
13. Choi J, Gyamfi J, Jang H, Koo JS. The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol 2018;33(2):133-45.
14. Schmieder A, Michel J, Schönhärt K, Goerdts S, Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012;22(4):289-97.
15. De Beule N, De Veirman K, Maes K, et al. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. J Pathol 2017; 241(4):534-46.
16. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013;229(2):176-85.
17. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011(1):54-67.
18. Dijkstra EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013;73(8):2480-92.
19. Liu Z, Xie Y, Xiong Y, Liu S, Qiu C, Zhu Z, Mao H, Yu M, Wang X. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett 2020;469:173-85.
20. Gerber HP, Olazoglu E, Grewal IS. Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res 2010;180:185-200.
21. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011;25(23):2465-79.
22. Gerber HP, Olazoglu E, Grewal IS. Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res 2010;180:185-200.
23. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496(7446):445-55.
24. Ginhoux F, Jung S. Monocytes and macrophages:
developmental pathways and tissue homeostasis. Nat Rev Immunol 2014;14(6):392-404.

25. Li C, Morvaridi S, Lam G, et al. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Front Physiol 2019;10:147.

26. Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE. Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res 2013;73(6):1752-63.

27. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov 2013;3(7):751-60.

Supplementary Tables

Table 1. Characteristic of individual studies retrieved from Gene Expression Omnibus for meta-analysis.

| Dataset   | Samples | Case/Control | Country | PMID       | Platforms          | Gene# | Gene chip                                      |
|-----------|---------|--------------|---------|------------|-------------------|-------|-----------------------------------------------|
| GSE11414  | 6       | 4/2          | Canada  | 18698372   | GPL6244           | 33297 | Affymetrix Human Gene 1.0 ST Array            |
| GSE12865  | 14      | 12/2         | Canada  | 19286668   | GPL6244           | 33297 | Affymetrix Human Gene 1.0 ST Array            |
| GSE14359  | 20      | 18/2         | Germany | 21166698   | GPL96             | 22283 | Affymetrix Human Genome U133A Array           |
| GSE16102  | 51      | 48/3         | USA     | 20028558   | GPL96             | 22283 | Affymetrix Human Genome U133A Array           |
| GSE42352  | 99      | 84/15        | Norway  | 24447333/23688189 | GPL10295 | 48701 | Illumina HumanWG-6 v2.0 expression beadchip |
| GSE42572  | 12      | 7/5          | Norway  | 26106474   | GPL13376          | 48701 | Illumina HumanWG-6 v2.0 expression beadchip |

According to the inclusion criteria, the following six GEO datasets from the NCBI were obtained: GSE11414, GSE12865, GSE14359, GSE16102, GSE42352, GSE42572. A total of 173 osteosarcoma samples and 29 normal tissue samples were used in meta-analysis. The GEO Platform Files (GPLs) from the six datasets were obtained using Affymetrix gene chips and Illumina gene chips.

Table 2. Characteristic of individual studies retrieved from Gene Expression Omnibus for EPIC.

| Dataset   | Samples | Case/Control | Country | PMID       | Platforms          | Gene# | Gene chip                                      |
|-----------|---------|--------------|---------|------------|-------------------|-------|-----------------------------------------------|
| GSE126209 | 11      | 6/5          | China   | NO         | GPL20301          | 60493 | Illumina HiSeq 4000 (Homo sapiens)             |
| GSE87624  | 47      | 44/3         | USA     | 29066513   | GPL11154          | 21887 | Illumina HiSeq 2000 (Homo sapiens)             |
| GSE99671  | 51      | 33/18        | Estonia | 29050494/29250102 | GPL20148 | 22775 | AB 5500xl-W Genetic Analysis System (Homo sapiens) |
| GSE57925  | 3       | 3/0          | USA     | 25961939   | GPL11154          | 22259 | Illumina HiSeq 2000 (Homo sapiens)             |

The following four GEO datasets from the NCBI were obtained: GSE126209, GSE87624, GSE99671, GSE57925. A total of 86 osteosarcoma samples and 26 normal tissue samples were used in EPIC analysis. The GEO Platform Files (GPLs) from the four datasets were obtained using Illumina HiSeq gene chips.